The story of Janet Woodcock’s illustrious career is not just one of professional achievements; it’s a tale of enduring partnerships, empathetic leadership, and unwavering commitment to science and patient care that will continue as she leaves public service this year.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
